This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.

Please cite this article as https://doi.org/10.4097/kja.19408
Skin test after anaphylaxis to sugammadex

SungJin Hong, M.D., PhD., JiYung Lee, M.D., Ph.D.
Department of Anesthesiology and Pain Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Running title: Skin test after anaphylaxis to sugammadex

Corresponding author: JiYung Lee, M.D., Ph.D.
Department of Anesthesiology and Pain Medicine, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 10 63-ro, Yeoungdeungpo-gu, Seoul 07345, Korea
Tel: 82-2-3779-1268, 82-10-6232-4673, Fax: 82-2-783-0368, Email: anesthalee@naver.com

Conflict of interest
No potential conflict of interest relevant to this article was reported

Authors’ contribution
SungJin Hong (Conceptualization; Investigation; Supervision)
JiYung Lee (Writing – original draft, review & editing)
Skin test after anaphylaxis to sugammadex

- Letter to the Editor -

We read the case report titled “Anaphylactic shock after sugammadex administration, induced by formation of a sugammadex-rocuronium complex - a case report” by Kim et al. [1] with great interest. As a result of their effective treatment, the patient fortunately, recovered. To find the causative agent of anaphylactic shock, the authors performed skin tests four days after anaphylaxis. However, it is recommended that skin testing is conducted at least four to six weeks after the occurrence of a suspected perioperative allergic reaction [2]. This time interval allows for the resolution of clinical symptoms and clearance of the suspected drugs and anti-allergic medications [3]. Skin tests performed earlier than this can result in a negative reaction due to mediator depletion after anaphylaxis. When tests are performed earlier than four weeks, only positive skin test results are useful and a negative skin test needs to be interpreted with caution. Therefore, the authors’ skin test was done too early and there is doubt about its reliability.

If the authors wanted to confirm skin reactivity, an appropriate positive control was necessary. Generally, appropriate positive and negative controls are always necessary in skin tests for suspected hypersensitivity reactions [4]. Usually, histamine is used as a positive control and saline as a negative control. Unfortunately, the authors did not include a positive control in their test. If the patient had shown a negative response to histamine, the patient's negative response to sugammadex should be a false result.

Certain drugs also decrease skin test responses and must be discontinued prior to a skin test. Antihistamines and glucocorticoids fall into this category. Five days of drug-free intervals after H1-
antihistamines and three days after less than 50 mg of short-term prednisolone equivalent are recommended because those drugs can decrease skin test reactivity [4]. Whether short and long-term systemic corticosteroids need to be stopped prior to testing is controversial [5]. The authors administered 60 μg/kg of dexamethasone and 50 μg/kg of chlorpheniramine after anaphylaxis. In addition to the skin test performed too early, drugs decreasing skin reactivity might have contributed to the negative response to all drugs.

If testing is performed earlier than four to six weeks, repeat testing after four to six weeks may be considered. In the case of negative skin test results, a second evaluation is advisable. The authors performed a skin test to sugammadex-rocuronium complex after a month. If the authors performed a skin test for sugammadex again with the sugammadex-rocuronium complex, the results would have been very clear. In our opinion, the interpretation of skin tests in this report was not complete because the skin tests did not meet the conditions of adequate timing after anaphylaxis and the appropriate use of positive and negative controls.

Presently, there are no established guidelines for skin testing for anaphylaxis to sugammadex. The reported allergenic epitopes were sugammadex, gamma-cyclodextrin, or sugammadex-rocuronium complex. Accurate skin tests will be helpful to identify the allergenic epitopes of sugammadex. We recommend performing skin tests at appropriate times, four to six weeks after anaphylaxis and the use of positive and negative controls.
References


